Insider Buying: Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $208,031.76 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 20,824 shares of the stock in a transaction dated Wednesday, July 29th. The shares were acquired at an average cost of $9.99 per share, for a total transaction of $208,031.76. Following the completion of the acquisition, the director owned 17,304,626 shares of the company’s stock, valued at approximately $172,873,213.74. This represents a 0.12% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 31st, Ra Capital Management, L.P. acquired 24,944 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $9.93 per share, for a total transaction of $247,693.92.
• On Friday, July 24th, Ra Capital Management, L.P. acquired 41,319 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $9.99 per share, with a total value of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. acquired 59,880 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $9.96 per share, with a total value of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. bought 84,124 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $9.93 per share, with a total value of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. bought 120,582 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.55 per share, for a total transaction of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. purchased 15,102 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.97 per share, for a total transaction of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. purchased 6,552 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. purchased 1,876 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. purchased 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.89 per share, with a total value of $1,110,298.77.

Artiva Biotherapeutics Price Performance

Shares of Artiva Biotherapeutics stock opened at $10.10 on Monday. The company has a market cap of $249.64 million, a price-to-earnings ratio of -2.85 and a beta of 2.18. The company’s 50 day moving average is $9.01 and its 200 day moving average is $7.53. Artiva Biotherapeutics, Inc. has a twelve month low of $2.22 and a twelve month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Wedbush upped their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. HC Wainwright increased their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Finally, Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the third quarter worth about $41,000. Bank of America Corp DE lifted its position in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $53,000. Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $58,000. Finally, Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.